Does the choice of alpha-AAS really make a difference?
Mutzebaugh
C
C
D045930:Anabolic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D019247:HIV Wasting Syndrome / Q000188:drug therapy*; D006801:Humans; D008099:Liver / Q000187:drug effects*; D012307:Risk Factors; D045165:Testosterone Congeners / Q000009:adverse effects* / Q000627:therapeutic use
D045930:Anabolic Agents; D045165:Testosterone Congeners